Research & Clinical Trials

Clinical research has been a focus of Virginia Pediatric Eye Center for over 35 years.  Currently, the center is actively participating in the Pediatric Eye Disease Investigative Group through funding from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The studies conducted by this group have led to new and substantial advances in pediatric ophthalmology and have resulted in better treatment options and outcomes for patients.  There are several research projects that are currently investigating new methods of treating various pediatric eye diseases.  Patients who meet study criteria for ongoing projects are offered the opportunity to enroll in clinical trials.  

For more information regarding these projects and clinical studies, please discuss with your pediatric ophthalmologist or pediatric optometrist:


Current Research Opportunities

CTX study - pediatric cataract study

- patients with bilateral cataracts may qualify for this study

- study involves free CTX testing


Luminopia C-AM-1D VR Device Pilot Study 4

- Luminopia study for amblyopia

-  the pilot data for this study was presented at AAPOS 2019  

- no longer recruiting, now recruiting for CAM2

- publications accepted


Luminopia One Vision Improvement Study C-AM-2

- Luminopia study for amblyopia

- Multi-center randomized controlled clinical trial for amblyopia

- Aged 4-7 years may qualify for enrollment


VERTEX studies in Cystic Fibrosis Patients

- these studies involve CF patients who are currently receiving treatment.  We provide eye exams

to rule out any developmental cataracts while on treatment.


Myopia Treatment Study

- myopia treatment study for near-sighted patients

For additional information on myopia treatment options, please see the following 2019 Myopia Consensus Statement from the World Society of Paediatric Ophthalmology and Strabismus Society.

WSPOS Myopia Consensus Statement


ATS20 - Big Dig Rush Binocular Treatment Game for Amblyopia

- This is a 16 week study with a younger cohort (4 - 7 yrs old) and older cohort (7 - 13 yrs old)


IXT5 - Overminus treatment for Intermittent Exotropia

- Ages 3 to 11 years

- publications accepted


IXT1 ext - Intermittent Exotropia Study 1 Extension

- this study is currently only in long term follow up for previous IXT1 patients


ROP1 - Phase 1 Bevacizumab Dosing Study for Retinopathy of Prematurity 

- Enrollment completed, patients in long-term follow up

- publications accepted

- presentations completed

- Dr Crouch presented at 2018 AAPOS Annual Meeting in Washington DC


ROP2Y - Bayley testing for ROP patients

- data on this study is currently being reviewed by the steering committee

- publication in development


CO2 - Pediatric Cataract Registry study

- this study has completed recruitment and is in follow up


SAS1 - Study of Adult Strabismus for Divergence Insufficiency, Convergence

Insufficiency, and small angle hypertropia

- this study has completed recruitment and is in follow up

- Dr Crouch presented at 2019 AAPOS Annual Meeting in San Diego


Upcoming studies:

ATS19 - Refractive surgery for amblyopia

- Dr. Martinson is serving on the steering committee and the launch date is pending


LUXTURNA Gene Testing

- Free gene testing is available for patients with Leber congenital amaurosis (LCA), Retinitis

pigmentosa (RP), Severe early childhood-onset retinal dystrophy (SECORD), Early-onset severe

retinal dystrophy (EOSRD), and Early childhood-onset retinitis pigmentosa (ECRP).  If you have

any with these conditions, please let us know.  You may call and ask to speak with our research coordinator.

Previous Protocols

  • Nasolacrimal duct obstruction (NLD1, NLD2, NLD3) 

  • Amblyopia treatment

  • Esotropia (CEOS)

  • Exotropia (IXT 1, 2, 3, 4, 5)

  • Pediatric optic neuritis

  • Retinopathy of Prematurity (ROP1, ROP2A)

  • VERTEX studies

  • Photoscreening positive predictive value

  • Pediatric cataract 

  • Pediatric glaucoma 

  • Adult strabismus (SAS1)